Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03364231
Title Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications

marginal zone B-cell lymphoma

Waldenstroem's macroglobulinemia

Therapies

Umbralisib

Age Groups: child | senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
TG Therapeutics Investigational Trial Site Washington District of Columbia 20007 United States Details
TG Therapeutics Investigational Trial Site Boston Massachusetts 02215 United States Details
TG Therapeutics Investigational Trial Site Hackensack New Jersey 07601 United States Details
TG Therapeutics Investigational Trial Site New York New York 10065 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field